AIRLINK 170.57 Decreased By ▼ -2.58 (-1.49%)
BOP 11.18 Increased By ▲ 0.53 (4.98%)
CNERGY 8.41 Decreased By ▼ -0.11 (-1.29%)
CPHL 99.73 Increased By ▲ 2.27 (2.33%)
FCCL 46.60 Decreased By ▼ -0.65 (-1.38%)
FFL 15.15 Decreased By ▼ -0.27 (-1.75%)
FLYNG 27.55 Decreased By ▼ -0.58 (-2.06%)
HUBC 137.78 Decreased By ▼ -1.13 (-0.81%)
HUMNL 12.92 Increased By ▲ 0.11 (0.86%)
KEL 4.54 No Change ▼ 0.00 (0%)
KOSM 5.36 Decreased By ▼ -0.19 (-3.42%)
MLCF 62.40 Increased By ▲ 0.14 (0.22%)
OGDC 212.16 Decreased By ▼ -2.59 (-1.21%)
PACE 5.42 Decreased By ▼ -0.13 (-2.34%)
PAEL 47.18 Increased By ▲ 2.32 (5.17%)
PIAHCLA 18.48 Decreased By ▼ -0.22 (-1.18%)
PIBTL 10.36 Decreased By ▼ -0.38 (-3.54%)
POWER 12.33 Increased By ▲ 0.07 (0.57%)
PPL 169.60 Decreased By ▼ -4.27 (-2.46%)
PRL 35.85 Decreased By ▼ -0.37 (-1.02%)
PTC 23.09 Decreased By ▼ -0.47 (-1.99%)
SEARL 96.26 Increased By ▲ 0.95 (1%)
SSGC 39.52 Increased By ▲ 0.39 (1%)
SYM 13.84 Decreased By ▼ -0.18 (-1.28%)
TELE 7.15 Decreased By ▼ -0.08 (-1.11%)
TPLP 10.03 Decreased By ▼ -0.26 (-2.53%)
TRG 63.48 Decreased By ▼ -1.20 (-1.86%)
WAVESAPP 9.99 Decreased By ▼ -0.05 (-0.5%)
WTL 1.31 Decreased By ▼ -0.02 (-1.5%)
YOUW 3.66 Decreased By ▼ -0.04 (-1.08%)
BR100 12,305 Decreased By -186.6 (-1.49%)
BR30 37,415 Decreased By -278.7 (-0.74%)
KSE100 114,853 Decreased By -1335.9 (-1.15%)
KSE30 35,217 Decreased By -533.1 (-1.49%)

French drugmaker Sanofi reported a fourth-quarter profit that came in-line with analysts’ estimates on Thursday, and said it would buy back 5 billion euros ($5.21 billion) in shares this year as it seeks to build investor confidence in its drug pipeline.

Sanofi, one of the world’s largest maker of vaccines and a leader in anti-inflammatory drugs, also said it expects sales to grow by a mid-to-high single-digit percentage in 2025, at a time the company transitions into a pure-play drugmaker.

Sanofi is close to selling a 50% stake in its consumer health business Opella to investor Clayton Dubilier & Rice, and said it expects the deal to close in the second quarter at the earliest.

Quarterly business operating income, excluding one-off items, fell by 7.7% to 2.08 billion euros but met the average analyst estimate in a poll posted on the company’s website.

Sales of its blockbuster asthma drug Dupixent rose 16% to 3.46 billion euros, compared to 3.61 billion euros expected on average by analysts in a company-provided poll.

The company said sales growth had been hit by fewer business days in the quarter compared to prior periods.

Investor expectations have been high for the anti-inflammatory drug, on which Sanofi partners with Regeneron , after it gained approval for a common lung condition called chronic obstructive pulmonary disease in September.

Sanofi profit slips on generic competition and currency effects

Sales of Beyfortus, a new treatment to protect newborns from a common respiratory virus, more than doubled to 841 million euros, beating estimates of 648 million euros.

Vaccines sales rose a currency-adjusted 10.8% to 2.18 billion euros in the quarter, ahead of a 1.91 billion euro analyst consensus.

Comments

200 characters